Current Report Filing (8-k)
November 07 2017 - 3:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2017
CHEMOCENTRYX, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35420
|
|
94-3254365
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
850 Maude Avenue, Mountain View, CA
|
|
94043
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
210-2900
(Former name
or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 7, 2017, ChemoCentryx,
Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2017. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form
8-K,
the information in this Current Report on Form
8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific
reference in such filing to this Current Report on Form
8-K.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CHEMOCENTRYX, INC.
|
|
|
|
|
Date: November 7, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Susan M. Kanaya
|
|
|
|
|
Name:
|
|
Susan M. Kanaya
|
|
|
|
|
Title:
|
|
Executive Vice President
Chief Financial and
Administrative Officer and Secretary
|
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2024 to May 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about ChemoCentryx Inc (NASDAQ): 0 recent articles
More Chemocentryx, Inc. News Articles